SURPASS | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

743 results for “SURPASS”

Trials

View all 38 →

SURPASS Retrospective Study

500 participants · First posted Mar 22, 2023

SURPASS Impella 5.5 Study

1,017 participants · First posted Oct 29, 2021

China Surpass Streamline Post-Market Study

11 participants · First posted Sep 16, 2022

Organizations

Surmasis Pharmaceutical, LLC

United States

Sargass Group Limited Liability Company

United States

News

View all 703 →

Ropeginterferon Alfa-2b Shows Promise in Hydroxyurea-Resistant Essential Thrombocythemia

Margetuximab Fails to Show Overall Survival Benefit Over Trastuzumab in HER2-Positive Breast Cancer

Ropeginterferon Alfa-2b Evaluated as Second-Line Therapy for High-Risk Essential Thrombocythemia in SURPASS-ET Trial

Page 1 of 75